127 related articles for article (PubMed ID: 32529857)
21. Oral antineoplastic agent interactions with medicinal plants and food: an issue to take into account.
Collado-Borrell R; Escudero-Vilaplana V; Romero-Jiménez R; Iglesias-Peinado I; Herranz-Alonso A; Sanjurjo-Sáez M
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2319-30. PubMed ID: 27316629
[TBL] [Abstract][Full Text] [Related]
22. Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy.
Siefried KJ; Mao L; Cysique LA; Rule J; Giles ML; Smith DE; McMahon J; Read TR; Ooi C; Tee BK; Bloch M; de Wit J; Carr A;
AIDS; 2018 Jan; 32(1):35-48. PubMed ID: 29135584
[TBL] [Abstract][Full Text] [Related]
23. Factors associated with drug interactions in elderly hospitalized in high complexity hospital.
Veloso RCSG; Figueredo TP; Barroso SCC; Nascimento MMGD; Reis AMM
Cien Saude Colet; 2019 Jan; 24(1):17-26. PubMed ID: 30698236
[TBL] [Abstract][Full Text] [Related]
24. Outpatient oral anticancer agent utilization and costs in Manitoba from 2003 to 2016: a population-based study.
Leong C; Czaykowski P; Geirnaert M; Katz A; Dragan R; Yogendran M; Raymond C
Can J Public Health; 2021 Jun; 112(3):530-540. PubMed ID: 33471346
[TBL] [Abstract][Full Text] [Related]
25. Potentially inappropriate medication use in older patients with breast and colorectal cancer.
Karuturi MS; Holmes HM; Lei X; Johnson M; Barcenas CH; Cantor SB; Gallick GE; Bast RC; Giordano SH
Cancer; 2018 Jul; 124(14):3000-3007. PubMed ID: 29689595
[TBL] [Abstract][Full Text] [Related]
26. Medication guide for the perioperative management of oral antineoplastic agents in cancer patients.
Villanueva-Bueno C; Escudero-Vilaplana V; Collado-Borrell R; Giménez-Manzorro Á; Ribed A; Marzal-Alfaro B; Revuelta-Herrero JL; Gonzalez-Haba E; Herranz A; Sanjurjo M
Expert Opin Drug Saf; 2022 Jan; 21(1):107-119. PubMed ID: 34357828
[TBL] [Abstract][Full Text] [Related]
27. High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate.
Jamani R; Lee EK; Berry SR; Saluja R; DeAngelis C; Giotis A; Emmenegger U
Eur J Clin Pharmacol; 2016 Nov; 72(11):1391-1399. PubMed ID: 27561266
[TBL] [Abstract][Full Text] [Related]
28. Pharmacists' perceived knowledge of and confidence in dispensing oral antineoplastic agents.
Dayer L; Dunn E; Pace A; Flowers S
J Am Pharm Assoc (2003); 2016; 56(2):141-4.e2. PubMed ID: 27000164
[TBL] [Abstract][Full Text] [Related]
29. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
[TBL] [Abstract][Full Text] [Related]
30. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
31. Clinical implications of food-drug interactions with small-molecule kinase inhibitors.
Veerman GDM; Hussaarts KGAM; Jansman FGA; Koolen SWL; van Leeuwen RWF; Mathijssen RHJ
Lancet Oncol; 2020 May; 21(5):e265-e279. PubMed ID: 32359502
[TBL] [Abstract][Full Text] [Related]
32. [Issues of oral targeted therapies in daily clinical practice: 5th edition of the congress of pharmacology of anticancer drugs].
Zaibet S; Vauchier C; Khoudour N; Roulleaux Dugage M; Korb-Savoldelli V; Alexandre J; Blanchet B; Goldwasser F; Thomas-Schoemann A; Bellesoeur A
Bull Cancer; 2018 Nov; 105(11):1102-1109. PubMed ID: 30309623
[TBL] [Abstract][Full Text] [Related]
33. Impact of dosing frequency (once daily or twice daily) on patient adherence to oral targeted therapies for hematologic malignancies: a retrospective cohort study among managed care enrollees.
Patel K; Sudhir VS; Kabadi S; Huang JC; Porwal S; Thakkar K; Pagel JM
J Oncol Pharm Pract; 2019 Dec; 25(8):1897-1906. PubMed ID: 30823852
[TBL] [Abstract][Full Text] [Related]
34. Potential drug interactions in patients with a history of cancer.
Chen L; Cheung WY
Curr Oncol; 2014 Apr; 21(2):e212-20. PubMed ID: 24764706
[TBL] [Abstract][Full Text] [Related]
35. Polypharmacy in patients with advanced cancer and pain: a European cross-sectional study of 2282 patients.
Kotlinska-Lemieszek A; Paulsen O; Kaasa S; Klepstad P
J Pain Symptom Manage; 2014 Dec; 48(6):1145-59. PubMed ID: 24780183
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer.
Hoemme A; Barth H; Haschke M; Krähenbühl S; Strasser F; Lehner C; von Kameke A; Wälti T; Thürlimann B; Früh M; Driessen C; Joerger M
Cancer Chemother Pharmacol; 2019 Apr; 83(4):763-774. PubMed ID: 30684020
[TBL] [Abstract][Full Text] [Related]
37. [Analysis of comorbidity and polypharmacy in middle-aged and elderly patients].
Su BB; Ma JX; Song W; Yuan J; Dong XY; Wan J
Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(25):1983-1987. PubMed ID: 32629601
[No Abstract] [Full Text] [Related]
38. Implementation of a pharmaceutical care programme for patients receiving new molecular-targeted agents in a clinical trial unit.
Riu G; Gaba L; Victoria I; Molas G; do Pazo F; Gómez B; Creus N; Vidal L
Eur J Cancer Care (Engl); 2018 Jan; 27(1):. PubMed ID: 26786594
[TBL] [Abstract][Full Text] [Related]
39. The effectiveness of therapeutic patient education on adherence to oral anti-cancer medicines in adult cancer patients in ambulatory care settings: a systematic review.
Arthurs G; Simpson J; Brown A; Kyaw O; Shyrier S; Concert CM
JBI Database System Rev Implement Rep; 2015 Jun; 13(5):244-92. PubMed ID: 26455611
[TBL] [Abstract][Full Text] [Related]
40. Polypharmacy, aging, and cancer.
Tam-McDevitt J
Oncology (Williston Park); 2008 Aug; 22(9):1052-5, discussion 1055, 1058, 1060. PubMed ID: 18777955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
